Edmond DE Rothschild Holding S.A. Acquires Shares of 19,000 RadNet, Inc. $RDNT
Edmond DE Rothschild Holding S.A. acquired 19,000 shares of RadNet, Inc. (NASDAQ:RDNT) during the second quarter, valued at approximately $1.17 million. This acquisition contributes to institutional investors collectively owning 77.9% of the company. RadNet recently surpassed quarterly earnings expectations, reporting $0.29 EPS against a $0.20 consensus, and saw a 25% year-over-year revenue increase to $622.7 million.
RTW INVESTMENTS, LP Buys RadNet Inc (RDNT) -- Shares Look 11% Overvalued on GF Value
RTW INVESTMENTS, LP increased its stake in RadNet Inc (RDNT) by acquiring 561,958 shares at $61.67 each, bringing its total holdings to 4,846,958 shares and raising the stock's weight in its portfolio to 2.96%. RadNet, a diagnostic imaging service provider, is currently valued as "Modestly Overvalued" by GuruFocus with a GF Value of $69.37, despite its historical performance and institutional interest. The firm's decision to increase its position aligns with its healthcare-focused investment strategy, betting on the sector's continued growth despite mixed financial indicators for RadNet.
Robotti Robert Invests $7.46 Million in RadNet, Inc. $RDNT
Robotti Robert has initiated a significant position in RadNet, Inc. (NASDAQ:RDNT) during the second quarter, investing $7.46 million for 120,972 shares, which now constitutes 1.2% of the firm's portfolio. This move aligns with high institutional ownership in RadNet, including other major investors like BlackRock and RTW Investments increasing their stakes. The company recently reported strong financial results with quarterly revenue up 25% year-over-year and EPS exceeding analyst estimates, contributing to a "Moderate Buy" consensus among analysts.
Surging Revenue With Softer Profits Might Change The Case For Investing In RadNet (RDNT)
RadNet (RDNT) reported strong Q2 2026 revenue growth but a decline in net income and EPS, highlighting a tension between top-line expansion and profitability challenges. The company's investment narrative is centered on its AI-focused imaging platform, particularly the recent launch of Reporting Pro, which aims to increase volume but also requires significant investment, impacting current earnings. Analysts have varied opinions on RadNet's future profitability and fair value, with some optimistic about AI-driven margin gains, while others caution about the risks of new acquisitions and AI projects not meeting expected returns.
Bank of America Corp DE Boosts Position in RadNet, Inc. $RDNT
Bank of America Corp DE has increased its stake in RadNet, Inc. (NASDAQ:RDNT) by 15.1% in the first quarter, now owning 589,610 shares valued at approximately $33.0 million. Institutional investors collectively hold 77.9% of RadNet's stock. RadNet recently reported strong quarterly revenue of $622.7 million, a 25% year-over-year increase, and earnings of $0.29 per share, surpassing analyst expectations.
RadNet (NASDAQ:RDNT) Raised to "Hold" at Zacks Research
Zacks Research has upgraded RadNet (NASDAQ:RDNT) from a "strong sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an $88 price target. The company recently reported strong quarterly results, beating EPS estimates with $0.29 and achieving a 25% year-over-year revenue increase to $622.72 million. Despite insider share sales, institutional investors hold a significant portion of RadNet's shares.
RTW Investments (RDNT) discloses 4.8M-share, 6.2% ownership position in RadNet
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 4,846,958 shares of RadNet, Inc. common stock, which represents a 6.2% stake in the company. This ownership is based on 78,634,236 shares outstanding as of May 8, 2026, with both parties holding shared voting and dispositive power over these shares. The shares are held directly by RTW-managed funds, entitling them to dividends and sale proceeds.
RadNet (NASDAQ: RDNT) files resale for 34,069 See-Mode milestone shares
RadNet Inc. (NASDAQ: RDNT) has filed to register for resale up to 34,069 shares of common stock. These shares are part of a contingent milestone payment to former shareholders of See-Mode Technologies Pte. Ltd. following its June 2, 2025 acquisition. The payment is tied to the achievement of specific FDA 510(k) milestones for a breast ultrasound detection product.
RadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
RadNet, Inc. (NASDAQ:RDNT) has received a "Moderate Buy" consensus recommendation from nine brokerages, with an average 12-month price target of $88. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and its stock opened at $77.31. Insider transactions show recent stock sales by the CEO and a director, while institutional investors hold a significant portion of the shares.
RadNet (RDNT) Stock Cools As Record Revenue Meets Profit Pressure
RadNet (RDNT) experienced a slight stock dip despite reporting record Q2 2026 revenue of US$622.7m and US$99.7m in adjusted EBITDA, marking a 25% increase in total revenue year-over-year. While the core imaging business and digital health segment showed strong growth, net income and basic EPS roughly halved due to cost pressures, integration efforts, and interest expenses. The company's new US$250m term loan and insider selling also raise some concerns for investors.
RADNET, INC. : B. RILEY RAISES TARGET PRICE TO $96 FROM $83
B. Riley has increased its target price for RADNET, INC. (RDNT.O) to $96 from $83. This article, attributed to Reuters, provides this key financial update without further elaboration on the reasons for the target price adjustment. It includes a disclaimer noting that the content reflects only the author's opinion and is not investment advice.
RadNet (RDNT) Stock Cools As Record Revenue Meets Profit Pressure
RadNet (RDNT) experienced a slight stock dip despite reporting record Q2 2026 revenue of US$622.7m and US$99.7m in adjusted EBITDA, driven by strong growth in both its core imaging business and Digital Health segment. However, net income and EPS nearly halved due to cost pressures and investments, while the company also added a US$250m term loan. Investors are now weighing the company's significant top-line growth against its profitability pressures and increased leverage.
California Court Holds Sexual Orientation Harassment Claims Are Exempt from Arbitration Under the EFAA
A California appellate court has ruled that sexual orientation harassment claims are exempt from arbitration under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021 (EFAA). This decision in Decloedt v. Radnet Management, Inc. affirms that harassment based on sexual orientation qualifies as sexual harassment under California's Fair Employment and Housing Act (FEHA), thereby triggering the EFAA's arbitration exemption. Employers are advised to review arbitration agreements, update anti-harassment policies, and ensure training addresses sexual orientation harassment to align with this evolving legal landscape.
RadNet (NASDAQ:RDNT) Stock Price Expected to Rise, Truist Financial Analyst Says
Truist Financial has increased its price target for RadNet (NASDAQ:RDNT) from $90 to $94, maintaining a "buy" rating, which implies a potential 24% upside. This follows RadNet's strong Q2 2026 performance, with revenue up 25% year-over-year to $622.7 million and EPS of $0.29, both exceeding estimates. The company also raised its 2026 guidance for revenue, adjusted EBITDA, and free cash flow due to high imaging demand and rapid growth in its Digital Health segment, despite some insider stock sales and a decline in year-over-year GAAP net income.
B. Riley Adjusts Price Target on RadNet to $96 From $83, Maintains Buy Rating
B. Riley has increased its price target for RadNet (RDNT) to $96 from $83, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst actions, including Truist also raising its price target for RadNet to $94 from $90. RadNet, a national provider of diagnostic imaging services, recently reported its Q2 2026 earnings.
E. Ohman J or Asset Management AB Increases Stock Position in RadNet, Inc. $RDNT
E. Ohman J or Asset Management AB significantly increased its stake in RadNet, Inc. by 1,144.3% in the second quarter, now owning 452,966 shares worth $27.9 million. This move comes as RadNet reported strong Q2 results with a 25% revenue increase and adjusted EPS exceeding expectations, leading to raised 2026 guidance. Despite some insider selling and mixed profitability metrics, analysts maintain a "Moderate Buy" consensus for the medical research company.
RadNet, Inc. Revenue Breakdown – FWB:PQIA
RadNet, Inc. generated 1.74 billion EUR in revenue last year, with its Imaging Center segment contributing the most at 1.69 billion EUR. The United States was the primary revenue source, accounting for 1.71 billion EUR. This information highlights the company's key revenue streams and geographic performance.
RadNet Q2 Earnings Call Highlights
RadNet (RDNT) reported record Q2 2026 revenue of $622.7 million and adjusted EBITDA of $99.7 million, driven by increased advanced imaging volumes, strategic acquisitions, and growth in its Digital Health segment. The company also announced FDA 510(k) clearance for its DeepHealth breast ultrasound AI solution and raised its imaging-center outlook for 2026.
RadNet, Inc. (RDNT) Investor Outlook: Capitalizing on a 23.99% Potential Upside in the Booming Diagnostics Sector
RadNet, Inc. (RDNT) is positioned as a significant player in the diagnostics sector with a market capitalization of $5.69 billion. Analysts project a 23.99% potential upside, driven by strong revenue growth (22.10%) and strategic investments in AI and DeepHealth OS. While the company shows a bullish trend with its stock price above moving averages and positive MACD, investors should note its high forward P/E ratio and current negative EPS when evaluating its financial health.
Earnings call transcript: RadNet tops Q2 2026 estimates, shares rise 6.1%
RadNet reported stronger-than-expected Q2 2026 results, with adjusted EPS of $0.29 and revenue of $622.7 million, exceeding analyst estimates. The company saw record total revenue and adjusted EBITDA, driven by growth in advanced imaging and digital health. Shares rose 6.09% in after-hours trading, and RadNet raised its full-year 2026 guidance for imaging center revenue, adjusted EBITDA, and free cash flow.
RadNet Jumps 8.2% on EPS Beat
RadNet shares surged 8.2% after the diagnostic imaging provider reported strong second-quarter earnings. The company posted an EPS of $0.29 on revenue of $622.7 million for the quarter ended June 2026, boosting its market capitalization to $6.0 billion. Investors will be watching if RadNet can maintain this positive earnings trajectory and capitalize on growth opportunities in the diagnostic imaging market.
RadNet touts ‘disproportionately higher’ growth in advanced imaging
RadNet Inc. reported "record" second-quarter results with a 25% year-over-year revenue increase, driven by disproportionately higher growth in advanced imaging procedures like MRI, CT, and PET/CT. The company revised its 2026 financial projections upwards, anticipating greater total net revenue and adjusted earnings, partly due to successful joint venture partnerships with hospital systems and the shift towards advanced modalities. RadNet attributed its success to increased procedural volumes, recent acquisitions, and growth in its digital health segment.
The Manufacturers Life Insurance Company Cuts Position in RadNet, Inc. $RDNT
The Manufacturers Life Insurance Company reduced its stake in RadNet, Inc. (NASDAQ:RDNT) by 35% in the first quarter, selling 18,543 shares and retaining 34,460 shares valued at $1.93 million. Despite a consensus "Moderate Buy" rating, analyst sentiment is mixed, with some downgrades and price target reductions. RadNet's Q1 revenue exceeded expectations, but the company reported an adjusted loss of $0.28 per share, missing anticipated results.
RadNet earnings beat by $0.09, revenue topped estimates
RadNet (NASDAQ: RDNT) announced second-quarter earnings per share of $0.29, surpassing analyst estimates by $0.09, and revenue of $622.7 million, exceeding the consensus of $610.01 million. The company projects FY 2026 revenue between $2.37 billion and $2.42 billion, below the analyst consensus of $2.49 billion. RadNet's stock has performed well, rising 36.64% in the last three months and 16.76% over the past year.
RadNet: Q2 Earnings Snapshot
The article provides a Q2 earnings snapshot for RadNet. However, the full content of the snapshot is not available in the provided text.
RadNet Reports Second Quarter Financial Results with Record
RadNet, Inc. reported record second-quarter financial results for 2026, with total company revenue increasing by 25.0% to $622.7 million and Adjusted EBITDA reaching $99.7 million. The Digital Health segment also saw significant growth, with revenue up 56.5% and Annual Recurring Revenue (ARR) increasing to $105.5 million. Due to this strong performance, RadNet has revised its full-year 2026 guidance upwards for Imaging Center revenue, Adjusted EBITDA, and Free Cash Flow.
Press Release: RadNet Reports Second Quarter Financial Results With Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
RadNet announced record second-quarter financial results with revenue of $428.1 million and Adjusted EBITDA of $75.5 million. The company also raised its 2026 financial guidance ranges due to the strong performance and the anticipated benefits from its continued growth and strategic initiatives. This positive outlook reflects robust operational execution and favorable market conditions.
RadNet Reports Record Second Quarter 2026 Revenue and Adjusted EBITDA, Raises Full-Year Imaging Center Guidance
RadNet, Inc. reported record financial results for the second quarter of 2026, with total revenue increasing 25% to $622.7 million and Adjusted EBITDA rising 22.7% to $99.7 million. The Digital Health segment showed substantial growth with a 56.5% revenue increase and nearly 97% surge in Annual Recurring Revenue, despite a decrease in its Adjusted EBITDA due to infrastructure investments. The company raised its full-year 2026 guidance for the Imaging Center segment, citing strong procedural volumes and successful partnerships.
BRIEF-RadNet Q2 EPS USD 0.1
RadNet reported its Q2 Earnings Per Share (EPS) as USD 0.1. The brief note from Refinitiv was published on TradingView News. To access the full article and more news, a subscription or further access might be required.
RadNet beats Q2 estimates, raises outlook as imaging demand surges (RDNT:NASDAQ)
RadNet (RDNT) surpassed Wall Street expectations for its second-quarter revenue and earnings, driven by a significant increase in demand for advanced diagnostic imaging and the expansion of its Digital Health segment. The company raised its full-year 2026 outlook for Imaging Center revenue and earnings, though the upper end of the guidance remains below current analyst consensus.
RadNet Inc (RDNT) Stock News Today
This article from TradingKey provides a brief update on RadNet Inc (RDNT) stock. It notes the current stock price, market capitalization, and a positive daily performance. The page indicates that more news, earnings, and analyst ratings for RadNet Inc will be coming soon.
RadNet (RDNT) To Report Earnings Tomorrow: Here Is What To Expect
RadNet (RDNT) is set to report its earnings tomorrow after market close. Analysts expect the diagnostic imaging company's revenue to grow 22.1% year-on-year, an improvement from the previous year. Despite a recent miss on EPS estimates, the company has a history of exceeding Wall Street's revenue expectations, and investor sentiment in the testing and diagnostics services segment is positive.
RadNet earnings in focus as profit return looms after Q1 miss
RadNet Inc. is expected to report second-quarter earnings, with analysts anticipating a rebound to profitability at 20 cents per share on revenues of $610 million, following a Q1 loss. Investors will closely watch for resolution of operational challenges and the performance of its digital health investments, particularly its DeepHealth subsidiary and AI acquisitions. The company's strategic growth initiatives and previous guidance raise confidence despite the earlier earnings miss.
RadNet, Inc. (RDNT) Stock Forecasts
Argus has raised its target price for RadNet Inc. (RDNT) to $73.00, noting the company's role as a national provider of diagnostic imaging services across two segments: Imaging Center and Digital Health. The current stock price for RDNT is $72.39. The article also lists other related research reports and daily insider picks.
A Look at RadNet Inc (RDNT) After 3.1% Decline -- GF Value $68.2
RadNet Inc (RDNT) shares recently dropped 3.1%, but its GF Value™ indicates a 1.7% undervaluation at $67.06 compared to $68.23. The company has a strong GF Score™ of 82/100, driven by growth and valuation, despite being unprofitable and cash-flow negative. While gurus show positive sentiment, insider selling raises some caution for investors.
DeepHealth Receives FDA 510(k) Clearance for AI-Driven Breast Ultrasound Automation
DeepHealth, a subsidiary of RadNet, has received FDA 510(k) clearance for its AI-driven Breast Ultrasound platform. This technology automates lesion detection, ACR BI-RADS characterization, and reporting, aiming to standardize breast ultrasound examinations and improve cancer detection. RadNet plans to deploy this platform across its national network by the end of 2026, impacting over 700,000 annual breast ultrasound exams.
RadNet, Inc. (RDNT) Investor Outlook: A 40% Potential Upside In Healthcare Imaging
RadNet, Inc. (RDNT), a key player in diagnostic imaging, shows significant growth potential driven by its innovative integration of AI technologies like DeepHealth OS. Analysts are overwhelmingly positive, projecting a 40.72% upside with an average target price of $89.75. Despite a negative EPS and modest ROE, the company's strong revenue growth and bullish technical indicators make it an attractive opportunity for growth-oriented investors in the healthcare sector.
The Technical Signals Behind (RDNT) That Institutions Follow
This article analyzes the technical signals for Radnet Inc. (NASDAQ: RDNT), highlighting strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional risk-reward short setup. The piece also details AI-generated institutional trading strategies for different risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
What RadNet (RDNT)'s FDA-Cleared AI Breast Ultrasound Rollout Means For Shareholders
RadNet's subsidiary DeepHealth received FDA clearance for its AI-powered Breast Ultrasound tool, which automates lesion detection and reporting. This AI solution will be deployed across RadNet's network for an estimated 700,000 eligible breast ultrasound studies annually, potentially improving imaging workflows and efficiency. While this reinforces RadNet's strategy of leveraging AI for profitability, investors should also consider risks like reimbursement pressure and ongoing investment needs.
What RadNet (RDNT)'s FDA-Cleared AI Breast Ultrasound Rollout Means For Shareholders
RadNet's subsidiary DeepHealth received FDA clearance for its AI-powered breast ultrasound tool, which will be deployed across RadNet's network for approximately 700,000 annual studies. This move aligns with RadNet's strategy of leveraging AI for improved workflow and scalability in outpatient imaging, although near-term challenges like reimbursement pressure and AI investment needs persist. The company projects significant revenue and earnings growth by 2029, with some analysts seeing a substantial upside to its current stock price.
DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
DeepHealth, a subsidiary of RadNet, Inc., has received FDA 510(k) clearance for its AI-powered DeepHealth Breast Ultrasound solution. This technology aims to standardize and improve the accuracy and efficiency of breast ultrasound imaging by automating lesion detection, characterization, and reporting. The solution is now commercially available in the U.S. and will be implemented across RadNet’s network, potentially benefiting over 700,000 breast ultrasound studies annually.
RadNet subsidiary DeepHealth wins FDA clearance for AI-powered breast ultrasound tool
DeepHealth, a RadNet subsidiary, has received FDA 510(k) clearance for its AI-powered breast ultrasound tool designed for lesion detection and characterization. The product boasts high accuracy and improved cancer detection sensitivity, with a commercial rollout beginning immediately in the US. Deployment is planned across RadNet centers by year-end, potentially impacting over 700,000 annual breast ultrasound exams.
The 10 largest imaging center operators in the US
A new analysis by Definitive Healthcare identifies the 10 largest imaging center corporations in the U.S. based on location count. RadNet tops the list with approximately 383 outposts, followed by The US Oncology Network. The article notes that while the outpatient imaging market remains fragmented, corporate-backed networks are expanding through acquisitions and new site development.
RadNet, Inc. Revenue Breakdown – GETTEX:PQIA
RadNet, Inc. reported a total revenue of 1.74 billion EUR last year, with its Imaging Center segment contributing the most at 1.69 billion EUR. The significant majority of this revenue, 1.71 billion EUR, was generated in the United States.
RDNT|RadNet Inc|Price:63.620|
This article provides a detailed company profile for RadNet Inc (RDNT), a national provider of diagnostic imaging services. It covers the company's business scope, including its extensive network of outpatient imaging centers and its digital health segment focusing on AI solutions for medical imaging. The article also lists key financial data, market performance indicators, and details about the company's executives and major shareholders.
RadNet Inc (RDNT) Institutional Confidence
RadNet Inc (RDNT) has a strong institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion has increased by 12.32% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder. Several major institutional investors like BlackRock, Kaminsky, RTW Investments, and T. Rowe Price Associates hold significant stakes in the company.
RDNT|RadNet Inc|Price:61.460|Chg%:-0.110
This article provides a comprehensive stock analysis of RadNet Inc (RDNT) by TradingKey, highlighting its strong fundamentals and growth potential, despite a recent turn to loss. The company is currently considered fairly valued and has high institutional ownership, including a significant holding by George Soros. Analysts have issued "Buy" ratings with a target price indicating a 45.77% upside, while the stock is performing with average stability in the short term.
RadNet Inc (RDNT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of RadNet Inc's (RDNT) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article presents a placeholder for dividend details, suggesting a lack of historical dividend data for RDNT.
RadNet, Inc. Revenue Breakdown – TRADEGATE:PQIA
RadNet, Inc. (TRADEGATE:PQIA) generated 1.74 billion EUR in revenue last year, with its Imaging Center segment contributing the most at 1.69 billion EUR. The United States was the largest geographical contributor, accounting for 1.71 billion EUR of the revenue. This data represents a slight decrease in overall revenue compared to the previous year's 1.73 billion EUR from the Imaging Center segment and 1.74 billion EUR from the United States.
RDNT|RadNet Inc|Price:61.570|Chg%:+0.590
This article provides a detailed financial summary of RadNet Inc (RDNT), offering an overview of its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and various margin percentages over several quarters and fiscal years. The report also includes upcoming earnings dates and analyst ratings, presenting a comprehensive financial analysis for investors.
